

# David Matthews

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/719631/david-matthews-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126  
papers

58,714  
citations

50  
h-index

130  
g-index

130  
ext. papers

65,710  
ext. citations

9.9  
avg, IF

7.33  
L-index

#	Paper	IF	Citations
126	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 106-114	6.7	2
125	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 174, 108737	7.4	12
124	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	2
123	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2116-2124	6.7	9
122	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2395-2401	6.7	1
121	Exploring pain interference with motor skill learning in humans: a protocol for a systematic review. <i>BMJ Open</i> , <b>2021</b> , 11, e045841	3	0
120	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , <b>2021</b> , 64, 2012-2025	10.3	6
119	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , <b>2021</b> , 324, 165-172	3.2	2
118	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , <b>2021</b> , 77, 23-34.e1	7.4	12
117	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 822-831	6.7	6
116	Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 245-251	6.7	1
115	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 141	8	
114	Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2707-2715	6.7	0
113	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. <i>Diabetologia</i> , <b>2020</b> , 63, 1440-1452	10.3	81
112	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 57-66	7.9	44
111	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 335-345	6.7	27
110	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 530-539	6.7	10

109	Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 2465-2476	3.6	4
108	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 278-286	8	70
107	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2199-2203	6.7	2
106	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1519-1529	40	106
105	Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lankans. <i>BMC Endocrine Disorders</i> , <b>2019</b> , 19, 11	3.3	8
104	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2240-2247	6.7	7
103	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2591-2593	16.7	89
102	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , <b>2019</b> , 62, 926-938	10.3	65
101	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 188-193	6.7	20
100	Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2019</b> , 13, 3057-3063	8.9	2
99	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , <b>2019</b> , 62, 1854-1867	10.3	29
98	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1-13	3.6	12
97	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 2229-2242	12.7	57
96	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 454-466	6.7	57
95	Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2019</b> , 36, 505-513	3.5	11
94	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. <i>Stroke</i> , <b>2019</b> , 50, 396-404	6.7	32
93	Prevalence, patterns, and associations of dyslipidemia among Sri Lankan adults-Sri Lanka Diabetes and Cardiovascular Study in 2005-2006. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 447-454	4.9	10
92	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. <i>Diabetes Care</i> , <b>2018</b> , 41, 163-170	14.6	30

91	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 691-704	18.1	304
90	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 889-897	6.7	114
89	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). <i>Circulation</i> , <b>2018</b> , 137, 323-334	16.7	284
88	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2255-2263	6.7	39
87	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 143, 1-14	7.4	28
86	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 387-393	6.7	101
85	Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 926-935	6.7	78
84	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 843-851	4	14
83	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 644-657	59.2	3789
82	Junior hospital doctors-time to rethink the terminology. <i>Lancet, The</i> , <b>2017</b> , 390, 2033-2034	40	
81	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , <b>2016</b> , 39, 694-700	14.6	130
80	Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 289-94	6.7	18
79	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies <b>2016</b> , 471-492		
78	Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 129	8.7	52
77	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). <i>BMC Endocrine Disorders</i> , <b>2016</b> , 16, 42	3.3	10
76	Community Interventions for Health can support clinicians in advising patients to reduce tobacco use, improve dietary intake and increase physical activity. <i>Journal of Clinical Nursing</i> , <b>2016</b> , 25, 3167-3173 <sup>3,2</sup>		2
75	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 82-91	6.7	65
74	Tobacco smoking among school children in Colombo district, Sri Lanka. <i>Asia-Pacific Journal of Public Health</i> , <b>2015</b> , 27, NP278-87	2	4

73	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , <b>2015</b> , 38, e128-9	14.6	21
72	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , <b>2015</b> , 6, 289-302	3.6	32
71	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 140-9	14.6	1906
70	Epidemiology, aetiology and pathogenesis of type 2 diabetes <b>2015</b> , 93-102		
69	Clinical management of hyperglycaemia in type 2 diabetes <b>2015</b> , 103-111		
68	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 1065-74	6.7	45
67	Successful up-scaled population interventions to reduce risk factors for non-communicable disease in adults: results from the International Community Interventions for Health (CIH) Project in China, India and Mexico. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120941	3.7	11
66	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2015</b> , 58, 429-42	10.3	496
65	Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1392-406	59.2	415
64	Evaluation of physical activity among adults with diabetes mellitus from Sri Lanka. <i>International Archive of Medicine</i> , <b>2014</b> , 7, 15		12
63	Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. <i>Diabetic Medicine</i> , <b>2014</b> , 31, 1178-84	3.5	31
62	Evaluation of common type 2 diabetes risk variants in a South Asian population of Sri Lankan descent. <i>PLoS ONE</i> , <b>2014</b> , 9, e98608	3.7	6
61	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 262-74	8	596
60	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 217-223. e114-9	14.9	256
59	Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 204-12	6.7	106
58	Expansion of the homeostasis model assessment of $\beta$ cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. <i>Diabetes Care</i> , <b>2013</b> , 36, 2324-30	14.6	75
57	Methodology for quantifying fasting glucose homeostasis in type 2 diabetes: observed variability and lability. <i>Journal of Diabetes Science and Technology</i> , <b>2013</b> , 7, 640-5	4.1	3
56	NIHR Diabetes Research Network: the gold standard for clinical trials?. <i>Practical Diabetes</i> , <b>2012</b> , 29, 317-319		

55	NIHR Diabetes Research Network: recruitment, recruitment, recruitment. <i>Practical Diabetes</i> , <b>2012</b> , 29, 369-370	0.7	
54	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2012</b> , 35, 1364-79	14.6	2713
53	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2012</b> , 344, e1369	5.9	309
52	ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. <i>Diabetologia</i> , <b>2012</b> , 55, 2856-2857	10.3	5
51	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2012</b> , 55, 1577-96	10.3	1108
50	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Spectrum</i> , <b>2012</b> , 25, 154-171	1.9	22
49	Do clinical research networks work? The NIHR diabetes research network after 6 years. <i>Clinical Investigation</i> , <b>2012</b> , 2, 971-974		
48	Community Interventions for Health (CIH): A novel approach to tackling the worldwide epidemic of chronic diseases. <i>CVD Prevention and Control</i> , <b>2011</b> , 6, 47-56		32
47	Banting Memorial Lecture 2010 <sup>^</sup> . Type 2 diabetes as an 'infectious' disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , <b>2011</b> , 28, 2-9	3.5	36
46	Banting Memorial Lecture: reply from Matthews and Matthews. Type2 diabetes as an 'infectious' disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , <b>2011</b> , 28, 880	3.5	
45	Remote assessment of diabetic foot ulcers using a novel wound imaging system. <i>Wound Repair and Regeneration</i> , <b>2011</b> , 19, 25-30	3.6	42
44	Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study. <i>Evidence-Based Medicine</i> , <b>2011</b> , 16, 45-6		5
43	Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 780-9	6.7	163
42	Prevalence of overweight and obesity in Sri Lankan adults. <i>Obesity Reviews</i> , <b>2010</b> , 11, 751-6	10.6	79
41	Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. <i>Diabetes Care</i> , <b>2010</b> , 33, 730-2	14.6	74
40	An assessment of low-carbohydrate or low-fat diets for weight loss at 2 year follow-up <b>2010</b> , 27, 363		1
39	Impending type 2 diabetes. <i>Lancet, The</i> , <b>2009</b> , 373, 2178-9	40	3
38	<b>2009</b> ,		12

37	10-year follow-up of intensive glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1577-89	59.2	5246
36	Long-term follow-up after tight control of blood pressure in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1565-76	59.2	557
35	Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2008</b> , 5, 216-8	3.3	35
34	N of 1 trials in diabetes: making individual therapeutic decisions. <i>Diabetologia</i> , <b>2008</b> , 51, 921-5	10.3	35
33	Grand challenges in chronic non-communicable diseases. <i>Nature</i> , <b>2007</b> , 450, 494-6	50.4	459
32	Higher body mass index is associated with irregular and suppressed insulin pulsatility. <i>Diabetes, Obesity and Metabolism</i> , <b>2007</b> , 9, 603-4	6.7	1
31	The UK Diabetes Research Network--an opportunity and a challenge. <i>Diabetic Medicine</i> , <b>2007</b> , 24, 7-9	3.5	7
30	Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. <i>Thorax</i> , <b>2007</b> , 62, 969-74	7.3	287
29	Pioglitazone/Metformin. <i>Drugs</i> , <b>2006</b> , 66, 1878-1880	12.1	
28	The diabetes epidemic in Sri Lanka - a growing problem. <i>Ceylon Medical Journal</i> , <b>2006</b> , 51, 26-8	0.7	29
27	Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2005</b> , 70, 53-62	7.4	59
26	Chris Feudtner, Bittersweet: diabetes, insulin and the transformation of illness, Studies in Social Medicine, Chapel Hill and London, University of North Carolina Press, 2003, pp. xxii, 290, illus., £22.95, US\$29.95 (hardback 0-8078-2791-6).. <i>Medical History</i> , <b>2005</b> , 49, 117-118	0.2	
25	Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2005</b> , 21, 167-74	7.5	132
24	Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2005</b> , 48, 1093-104	10.3	136
23	Review: Sulphonylureas and the rise and fall of beta-cell function. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2005</b> , 5, 192-196		2
22	Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. <i>JAMA Ophthalmology</i> , <b>2004</b> , 122, 1631-40		317
21	Recent advances in the monitoring and management of diabetic ketoacidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2004</b> , 97, 773-80	2.7	66
20	An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. <i>Diabetic Medicine</i> , <b>2004</b> , 21, 568-76	3.5	97

19	Use and abuse of HOMA modeling. <i>Diabetes Care</i> , <b>2004</b> , 27, 1487-95	14.6	3233
18	Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2002</b> , 19, 465-9	3.5	35
17	Children with type 2 diabetes: the risks of complications. <i>Hormone Research in Paediatrics</i> , <b>2002</b> , 57 Suppl 1, 34-9	3.3	21
16	UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. <i>Diabetologia</i> , <b>2001</b> , 44, 156-63	10.3	684
15	Insulin resistance and $\beta$ cell function - a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , <b>2001</b> , 3, 28-33	6.7	27
14	The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice. <i>Diabetic Medicine</i> , <b>2001</b> , 18, 640-5	3.5	68
13	Dietary advice? Authors' response and erratum for 'Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)'. <i>Diabetic Medicine</i> , <b>2001</b> , 18, 251-251	3.5	
12	Insulin resistance and beta-cell function - a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , <b>2001</b> , 3 Suppl 1, 28-33	6.7	3
11	Insulin resistance and beta-cell function--a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , <b>2001</b> , 3 Suppl 1, S28-33	6.7	5
10	Assessment of the effects of insulin secretagogues in humans. <i>Diabetes, Obesity and Metabolism</i> , <b>2000</b> , 2, 271-83	6.7	1
9	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <i>BMJ: British Medical Journal</i> , <b>2000</b> , 321, 412-9		1350
8	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. <i>BMJ: British Medical Journal</i> , <b>2000</b> , 321, 405-12		5694
7	Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. <i>Diabetologia</i> , <b>1999</b> , 42, 1107-12	10.3	100
6	UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. <i>Diabetic Medicine</i> , <b>1998</b> , 15, 297-303	3.5	218
5	Correct homeostasis model assessment (HOMA) evaluation uses the computer program. <i>Diabetes Care</i> , <b>1998</b> , 21, 2191-2	14.6	1479
4	Acute effect of fructose on postprandial lipaemia in diabetic and non-diabetic subjects. <i>British Journal of Nutrition</i> , <b>1998</b> , 80, 169-175	3.6	59
3	Unbiased and flexible iterative computer program to achieve glucose clamping. <i>Diabetes Care</i> , <b>1989</b> , 12, 156-9	14.6	26
2	Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. <i>Diabetologia</i> , <b>1985</b> , 28, 412-9	10.3	23633



1 Control of pulsatile insulin secretion in man. *Diabetologia*, **1983**, 24, 231-7

10.3 130